You see a 2-month-old for a well-child visit. She is breastfed and nurses every 2 to 3 hours during the day, but her mother reports she is not nursing as vigorously as before.
You see a 2-month-old for a well-child visit. She is breastfed and nurses every 2 to 3 hours during the day, but her mother reports she is not nursing as vigorously as before. She sleeps one 4-hour block at night. Birth weight was 7 pounds 5 ounces. Weight gain over the last 2 weeks reveals gain of 5 ounces per week. Physical examination reveals the following: HEENT exam is benign, lung sounds are clear, a new III/VI systolic ejection murmur is noted along the left lower sternal border, cap refill is brisk, skin is pink and moist, and abdominal exam is benign.
Post an explanation of the differential diagnosis for the patient in the case study you selected. Explain which is the most likely diagnosis for the patient and why. Include an explanation of unique characteristics of the disorder you identified as the primary diagnosis. Then, explain a treatment and management plan for the patient, including appropriate dosages for any recommended treatments. Finally, explain strategies for educating patients and families on the treatment and management of the respiratory, cardiovascular, and/or genetic disorder.
Order This Solution
49051 Millions developed by 10% and working benefit in 2009 was 15012 Millions that developed by 6%. Roche is contributed CHF. 9874 Millions on R&D in 2009. The free trade stream out 2009 was 8893 that was 79% more than 2008. The aggregate representative of Roche are 81507. Out of them 80115 are changeless. The Sales commitment is more from US that is 38% than West Europe that is 28%. Since pharmaceutical advertising exercises impact the endorsing conduct of specialists, it is of most extreme significance to basically dissect the cases made in the limited time material of the medications. The degree to which pharmaceutical organizations advance the benefits of their items and applicable clinical trails give to specialists are not examined in Pakistan. The consequences of the present logical examination demonstrate that untrustworthy and one-sided claims with respect to the pharmaceutical items are uncontrolled in Pakistan. These medication advancements impact the recommending conduct of the General Practitioners, Consultants in this manner representing one of the possibly significant reasons for outlandish solution. Roche Pakistan Ltd is a Member of IFPMA and PMA and take after their moral business rules to offer its items. Roche Paksitan Ltd is at sixth positioning in Pakistan Pharmaceutical Market and its yearly deal is Rs. 5.2 Billions out of 2009 in Pakistan.>GET ANSWER